Adolescents and young adults with a "rare" cancer: Getting past semantics to optimal care for patientswith germ cell tumors

Oncologist

Volumn 19, Issue 7, 2014, Pages 689-692

  Stoneham, Sara J ^a   Hale, Juliet P ^b   Rodriguez Galindo, Carlos ^c   Dang, Ha ^d   Olson, Thomas ^e   Murray, Matthew ^f,g   Amatruda, James F ^h   Thornton, Claire ⁱ   Suren Arul, G ^j   Billmire, Deborah ^k   Krailo, Kmark ^d   Stark, Dan ^l   Covens, Al ^m   Hurteau, Jean ⁿ   Stenning, Sally ^o   Nicholson, James C ^f   Gershenson, David ^h   Lindsay Frazier, A ^c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^f CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ ROYAL VICTORIA HOSPITAL   (United Kingdom)

^j BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^k RILEY HOSPITAL FOR CHILDREN   (United States)

^l ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^m UNIVERSITY OF TORONTO   (Canada)

ⁿ NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^o MEDICAL RESEARCH COUNCIL   (United Kingdom)

more..

Author keywords

Adolescence; Germ cell tumors; Risk stratification; Young adults

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; TUMOR MARKER; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); EDITORIAL; FUNDING; GERM CELL TUMOR; HEALTH CARE SYSTEM; HUMAN; LIFE EXPECTANCY; OSTEOSARCOMA; PATIENT CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SEMANTICS; TESTIS CANCER; ADOLESCENT; ADULT; CHEMICALLY INDUCED; CLASSIFICATION; FEMALE; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASES; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; YOUNG ADULT;

EID: 84903608813     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0009     Document Type: Editorial

References (43)

1. Rates for 15 to 24 year olds in England. http:// www.nwcis.nhs.uk/tya/tya-incidence/incidencerates-15-24.aspx.
2. Surveillance of rare cancers in Europe. Available at http://www.rarecare.eu. Accessed November 26, 2013.
3. Smith MA, Seibel NL, Altekruse SF et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol 2010;28:2625-2634.
4. Draper GJ, Kroll ME, Stiller CA. Childhood cancer. Cancer Surv 1994;19-20:493-517.
5. Schneider DT, Calaminus G, Koch S et al. Epidemiologic analysis of 1,442 children and adolescents registered in the German germ cell tumor protocols. Pediatr Blood Cancer 2004;42:169-175.
6. Poynter JN, Amatruda JF, Ross JA. Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. Cancer 2010;116:4882-4891.
7. Arora RS, Alston RD, Eden TO et al. Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003. Cancer 2012;118:4290-4297.
8. Geraci M, Birch JM, Alston RD et al. Cancer mortality in13to 29-year-olds in EnglandandWales, 1981-2005. Br J Cancer 2007;97:1588-1594.
9. Travis LB, Fosså SD, Schonfeld SJ et al. Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-1365.
10. Fung C, Fossa SD, MilanoMTet al. Solid tumors after chemotherapy or surgery for testicular nonseminoma: A population-based study. J Clin Oncol 2013;31:3807-3814.
11. Woodward E, Jessop M, Glaser A et al. Late effects in survivors of teenage and young adult cancer: Does age matter? Ann Oncol 2011;22: 2561-2568.
12. Tothill P, Klys HS, Matheson LM et al. The longterm retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 1992; 28A:1358-1361.
13. Gietema JA, Meinardi MT, Messerschmidt J et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000;355:1075-1076.
14. BrouwersEE, HuitemaAD, BeijnenJHetal. Longterm platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 2008;8:7.
15. Gerl A, Schierl R. Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer. Acta Oncol 2000;39:519-522.
16. Greene MH. Is cisplatin a human carcinogen? J Natl Cancer Inst 1992;84:306-312.
17. Travis LB, Holowaty EJ, Bergfeldt K et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340:351-357.
18. Travis LB, Andersson M, GospodarowiczMet al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92:1165-1171.
19. Vancurová M, Procházková J, SrbV. Monitoring of effects of cis-diamminedichloroplatinum II (Platidiam). Part II. Tests for mutagenic activity in the indicator system of Salmonella typhimurium hisstrains (Ames test). Neoplasma 1985;32:307-312.
20. Sprauten M, Darrah TH, Peterson DR et al. Impact of long-termserum platinum concentrations on neuro-and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol 2012;30: 300-307.
21. Karjalainen S, Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ 1989;299: 1069-1072.
22. Majumdar SR, Roe MT, Peterson ED et al. Better outcomes for patients treated at hospitals that participate in clinical trials. Arch Intern Med 2008;168:657-662.
23. Peppercorn JM, Weeks JC, Cook EF et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review. Lancet 2004;363:263-270.
24. Ferrari A, Montello M, Budd T et al. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr Blood Cancer 2008;50 (Suppl):1101-1104.
25. FernL, Davies S, EdenTetal. Rates ofinclusionof teenagers and young adults in England into National Cancer Research Network clinical trials: Report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group. Br J Cancer 2008;99:1967-1974.
26. Bleyer A. Adolescent and young adult (AYA) oncology: The first A. Pediatr Hematol Oncol 2007; 24:325-336.
27. Bleyer A, Budd T, Montello M. Older adolescents and young adults with cancer and clinical trials: Lack of participation and progress in North America. In: Bleyer A, Barr RD, Albritton KH et al., eds. Cancer inAdolescents and Young Adults. Berlin, Germany: Springer Verlag, 2007:71-82.
28. Fern LA, Whelan JS. Recruitment of adolescents and young adults to cancer clinical trials-international comparisons, barriers, and implications. Semin Oncol 2010;37:e1-e8.
29. Whelan JS, Fern LA. Poor accrual of teenagers and young adults into clinical trials in the UK. Lancet Oncol 2008;9:306-307.
30. Purkayastha D, O'Hara C, Moran T. Routes to Diagnosis: Investigating the Different Pathways for Cancer Referrals in England for Teenagers and Young Adults. London, U.K.: National Cancer Intelligence Network, 2013.
31. InternationalGermCellConsensus Classification: A prognostic factor-based staging system for metastatic germcell cancers. InternationalGermCell Cancer Collaborative Group. J Clin Oncol 1997;15:594-603.
32. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. Available at http://seer.cancer.gov/archive/publications/aya/. Accessed March 16, 2014.
33. SEERstat fact sheets: Testis cancer. Available at http://seer.cancer.gov/statfacts/html/testis.html. Accessed March 16, 2014.
34. Abrantes F, Ribeiro K, Rodriguez-Galindo C et al. Germ Cell Tumours. Pediatric blood & cancer special issue: 44th congress of the international society of paediatric oncology, London, United Kingdom, 5th-8th October 2012;59:965-1152.
35. Marina N, Bielack S, Whelan J et al. International collaboration is feasible in trials for rare conditions: The EURAMOS experience. Cancer Treat Res 2009;152:339-353.
36. de Wit R, Skoneczna I, Daugaard G et al. Randomized phase III study comparing paclitaxelbleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: Intergroup study EORTC 30983. J Clin Oncol 2012;30: 792-799.
37. Christian JA, Huddart RA, Norman A et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003;21:871-877.
38. Grimison PS, Thomson DB, Stockler M et al. Accelerated BEP for advanced germ cell tumors. J Clin Oncol 2011;29(suppl).
39. Rimmer Y, Chester J, Joffe J et al. Accelerated BEP:AphaseI trialofdose-denseBEPforintermediate and poor prognosis metastatic germcell tumour. Br J Cancer 2011;105:766-772.
40. Fizazi K, Pagliaro LC, Flechon A et al. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13. J Clin Oncol 2013; 31(suppl):LBA4500.
41. Teenage Cancer Trust Factsheet. Available at http://www.teenagecancertrust.org/workspace/ documents/Teenage-Cancer-Trust-Factsheet-2012. pdf. Accessed November 5, 2014.
42. National Collaborating Center for Cancer. Guidance for Cancer Services: Improving Outcomes in Children and Young People With Cancer. The Manual. London, U.K.: National Institute for Health and Clinical Excellence, 2005.
43. Freyer DR, Felgenhauer J, Perentesis J. Children's Oncology Group's 2013 blueprint for research: Adolescent and young adult oncology. PediatrBlood Cancer 2013;60:1055-1058.